Comparison · NCT00167180-sae
DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: serious adverse events. Trial comparisons, record NCT00167180-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00167180-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.533 | 0.301 | 0.752 | wilson | |
| Risk in group 2 | 0.0714 | 0.0246 | 0.19 | wilson | |
| Risk difference, group 1 minus group 2 | 0.462 | 0.201 | 0.685 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 7.47 | 2.27 | 24.5 | log | |
| Odds ratio, group 1 over group 2 | 14.9 | 3.15 | 70.1 | log | |
| Number needed to harm, for one more participant with a serious adverse event on DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg than on DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 2.16 | 1.46 | 4.97 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg | 8 | 15 | EG000 |
| Group 2 | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg | 3 | 42 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 Year
Source ClinicalTrials.gov
Trial
- Title
- Post Transplant Donor Lymphocyte Infusion
- NCT number
- NCT00167180
- Phases
- PHASE2
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
- Interventions
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Results first posted
- 2017-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00167180?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00167180-sae